ProMetic Life Sciences Inc.
TSX : PLI

ProMetic Life Sciences Inc.

July 11, 2008 16:05 ET

ProMetic Group Announces Appointment of Bruce Pritchard as Chief Financial Officer

MONTREAL, QUEBEC, CANADA--(Marketwire - July 11, 2008) - ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic") today announces the nomination of Mr. Bruce Pritchard as Chief Financial Officer for the ProMetic group following the departure of Mr. Stephane Archambault. Over the last two years Mr. Prichard served as Chief Financial Officer of ProMetic BioSciences Ltd, ProMetic's UK division and in addition assumed the role of Vice-President, Corporate Development at ProMetic in October 2007.

"Mr. Pritchard's years of experience at the senior levels in the biotech and pharmaceutical industries are very relevant to ProMetic at this stage of its growth. Bruce has a clear track record of streamlining cross-border finance functions. This coupled with his experience in structuring financial transactions from public and private sources will ensure that ProMetic is well placed to achieve its goals for continued growth," said Mr. Pierre Laurin, President and Chief Executive Officer of the ProMetic group. "Meanwhile, we greatly appreciate Mr. Archambault's significant contributions to ProMetic over the years and wish him every success in his future endeavours."

In addition, Dr. Ronald D. Guttmann will be retiring from ProMetic's Board of Directors, effective immediately, citing personal business activities. Mr. Laurin, on behalf of ProMetic's Board of Directors, wishes Dr. Guttmann well and thanks him for his valuable contributions to ProMetic's projects.

About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. (www.prometic.com) is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand™ technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematology and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Montreal (Canada), ProMetic has R&D facilities in the U.K., the U.S. and Canada, manufacturing facilities in the U.K. and business development activities in the U.S., Europe, Asia and in the Middle-East.

Forward Looking Statements

This press release contains forward-looking statements about ProMetic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations on page 21 of ProMetic's Annual Information Form for the year ended December 31, 2007, under the heading "Risk Factors". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.

Contact Information